Dr. Eric Pang is currently serving as acting Team Lead for the Device, Injectable and Peptide Team in the Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, within FDA’s Center for Drug Evaluation and Research. Dr. Pang specializes in the analysis and regulatory assessment of peptide and large-molecule drugs, with an expertise in generic peptide products, complex active ingredients, immunogenicity, and policy development. In his current role, he and his team develop product-specific guidances for complex generics, respond to controlled correspondence and pre-ANDA meeting requests, supports Agency responses to citizen petitions, and manages regulatory science projects related to generic complex combination products.
Dr. Pang has more than 15 years of experience at FDA, including roles as a researcher, reviewer, policy lead. He has been serving as subject matter expert on immunogenicity risk assessment for generic peptide products and comparative analysis for device combination products. Dr. Pang received his Ph.D. in Biochemistry from UCLA and undergraduate degrees in Molecular Cell Biology and Legal Studies from the University of California, Berkeley.
